WallStreetZenWallStreetZen

NASDAQ: CTOR
Citius Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTOR

Based on 1 analyst offering 12 month price targets for Citius Oncology Inc

Min Forecast
$6.00+500%
Avg Forecast
$6.00+500%
Max Forecast
$6.00+500%

Should I buy or sell CTOR stock?

Based on 1 analyst offering ratings for Citius Oncology Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CTOR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CTOR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CTOR stock forecasts and price targets.

CTOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-23

1 of 1

Forecast return on equity

Is CTOR forecast to generate an efficient return?

Company
102.17%
Industry
214.97%
Market
342.13%
CTOR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTOR forecast to generate an efficient return on assets?

Company
45.41%
Industry
117.16%
CTOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTOR earnings per share forecast

What is CTOR's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.05
Avg 2 year Forecast
$0.54

CTOR revenue forecast

What is CTOR's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$63.7M
Avg 2 year Forecast
$121.3M

CTOR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CTOR$1.00$6.00+500.00%Strong Buy
CRDL$0.95$9.00+843.40%Buy
CPIX$3.98N/AN/A
ASRT$9.07$45.00+396.14%Buy
ZYBT$1.15N/AN/A
View Top Pharmaceutical Stocks

Citius Oncology Stock Forecast FAQ

Is Citius Oncology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTOR) stock is to Strong Buy CTOR stock.

Out of 1 analyst, 1 (100%) are recommending CTOR as a Strong Buy, 0 (0%) are recommending CTOR as a Buy, 0 (0%) are recommending CTOR as a Hold, 0 (0%) are recommending CTOR as a Sell, and 0 (0%) are recommending CTOR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Oncology stock.

What is CTOR's earnings growth forecast for 2026-2027?

(NASDAQ: CTOR) Citius Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 40,584.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,192.97%.

Citius Oncology's earnings in 2025 is -$24,761,369.On average, 3 Wall Street analysts forecast CTOR's earnings for 2026 to be $4,324,690, with the lowest CTOR earnings forecast at $4,155,094, and the highest CTOR earnings forecast at $4,451,887.

In 2027, CTOR is forecast to generate $45,841,716 in earnings, with the lowest earnings forecast at $44,044,001 and the highest earnings forecast at $47,190,001.

What is CTOR's revenue growth forecast for 2026-2027?

(NASDAQ: CTOR) Citius Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3,625.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,472.57%.

Citius Oncology's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast CTOR's revenue for 2026 to be $5,403,318,747, with the lowest CTOR revenue forecast at $5,191,493,728, and the highest CTOR revenue forecast at $5,562,314,708.

In 2027, CTOR is forecast to generate $10,287,674,677 in revenue, with the lowest revenue forecast at $9,884,884,908 and the highest revenue forecast at $10,590,402,987.

What is CTOR's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: CTOR) forecast ROA is 45.41%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 117.16%.

What is CTOR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTOR price target, the average CTOR price target is $6.00, with the highest CTOR stock price forecast at $6.00 and the lowest CTOR stock price forecast at $6.00.

The Wall Street analyst predicted that Citius Oncology's share price could reach $6.00 by Sep 23, 2026. The average Citius Oncology stock price prediction forecasts a potential upside of 500% from the current CTOR share price of $1.00.

What is CTOR's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CTOR) Citius Oncology's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that CTOR's EPS will be $0.05 for 2026, with the lowest EPS forecast at $0.05, and the highest EPS forecast at $0.05. In 2027, CTOR's EPS is forecast to hit $0.54 (min: $0.52, max: $0.56).

What is CTOR's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: CTOR) forecast ROE is 102.17%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.